YahooAugust 13, 2026 at 12:14 PM NY22 days ago

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Companies in This Story